Drug Discovery World

JANUARY 4, 2023

China is expected to record the highest diagnosed prevalence of non-alcoholic fatty liver disease (NAFLD) in 2029, representing 44% of cases within the 16 major pharmaceutical markets (16MM). The post China’s clinical trial activity in NAFLD increasing appeared first on Drug Discovery World (DDW). Not yet a DDW member?

Clinical Trials 130

Clinical Trials Trials Pharmaceutical Companies Pharmaceuticals 130

Drug Discovery World

JANUARY 9, 2024

Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The therapy has shown positive results in Phase III trials in both breast and lung cancer.

Drugs 173

Drugs Therapies Treatment Virus 173

Drug Discovery World

MAY 15, 2024

million diagnosed cases of diabetic retinopathy in the nine major pharmaceutical markets, expected to grow to >17.7 million by 2029, according to GlobalData. Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration. Beech has over 25 years of biotech and pharmaceutical industry experience.

Disease 162

Disease Treatment Therapies Pharmaceuticals 162

Vial

MARCH 1, 2024

Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). billion by 2029. Throughout its journey, PPD has been committed to consistent quality and execution, customer-aligned service, and continuous innovation to accelerate clinical trial execution.

Clinical Trials 52

Clinical Trials Clinical Research Laboratories Trials 52

Drug Discovery World

OCTOBER 4, 2022

The pandemic might have affected the number of clinical trials taking place for cell and gene therapies, with activity decreasing by around 15% compared to 2020, but major therapies such as Novartis’ gene therapy drug for spinal muscular atrophy (SMA) Zolgensma still made it to market. . billion, compared to $19.9 Automation.

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

Agency IQ

JANUARY 26, 2024

MDR Article 78(14) sets out the original transition deadline in going from voluntary use of the coordinated assessment process to mandatory use as May 25, 2027; for IVDs, use of the coordinated procedure becomes mandatory in May 26, 2029 for all Member States, as set out in IVDR Article 74(14). Once the E.U.

Regulations 40

Regulations Compliance Laboratories Production 40

Agency IQ

FEBRUARY 2, 2024

The proposal will be discussed at the Council of the EU Working Party on Pharmaceuticals and Medical Devices, taking place January 30. Companion diagnostics (CDx) and cancer trials: In 2023, the MDCG published guidance documents on classifying CDx. This is an extremely recent development, and an emerging area.

FDA 40

FDA Regulations Laboratories Production 40